Physician profile
Mohammad Khizar Ali
NPI 1023428919
$3,156.53
in general payments reported to CMS, 2019-2025
25 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what a typical Pain Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $405).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $201 · 2022: $676 · 2023: $630 · 2024: $554 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,484.31 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Medtronic, INC. | $279.69 | 2025 | Inceptiv, Kyphon Express II Kyphopak Tray |
| Glaxosmithkline, LLC. | $228.06 | 2023 | Arexvy, Nucala |
| Ucb, INC. | $198.46 | 2022-2024 | Briviact, Zilbrysq |
| Axsome Therapeutics, INC. | $114.30 | 2025 | Symbravo |
| Alexion Pharmaceuticals, INC. | $103.49 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $100.62 | 2022-2025 | |
| Genentech USA, INC. | $83.15 | 2022-2025 | Ocrevus Zunovo, Ocrevus |
| Sk Life Science, INC. | $62.62 | 2024-2025 | |
| Philips North America LLC | $60.33 | 2021 | |
| Pfizer INC. | $50.96 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $48.11 | 2022 | |
| Genzyme Corporation | $41.57 | 2022 | |
| Biogen, INC. | $41.48 | 2025 | Vumerity, Tysabri |
| Lundbeck LLC | $36.44 | 2025 | Vyepti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $31.22 | 2022-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $27.36 | 2021 | |
| Neurocrine Biosciences, INC. | $24.43 | 2023 | Ingrezza, Ongentys |
| Acorda Therapeutics, INC | $23.95 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $22.59 | 2023 | Relyvrio |
| Lilly USA, LLC | $21.63 | 2022 | |
| Arbor Pharmaceuticals, INC. | $21.29 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.95 | 2022 | |
| Celgene Corporation | $17.19 | 2022 | |
| Eisai INC. | $15.33 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.